Travere Therapeutics has received U.S. FDA approval for its Filspari (sparsentan) for treatment of focal segmental glomerulosclerosis (FSGS). FSGS Defined FSGS is a rare proteinuric kidney disorder, in both children and adults, characterized by progressive scarring of the kidney. A main symptom is proteinuria, in which protein leaks into the urine as the kidney’s normal filtration mechanism breaks down. Ultimately, this often leads to kidney failure. FSGS without nephrotic syndrome, whi...